191 related articles for article (PubMed ID: 24673513)
1. Randomized, double-blind, placebo-controlled, multiple-dose study of the safety, tolerability and pharmacokinetics of benvitimod, a candidate drug for the treatment of psoriasis.
Zhao L; Chen X; Cai L; Zhang C; Wang Q; Jing S; Chen G; Li J; Zhang J; Fang Y
J Clin Pharm Ther; 2014 Aug; 39(4):418-23. PubMed ID: 24673513
[TBL] [Abstract][Full Text] [Related]
2. Use of a dose-response model to guide future clinical trial of benvitimod cream to treat mild and moderate psoriasis.
Zang YN; Jiang DL; Cai L; Chen X; Wang Q; Xie ZW; Liu Y; Zhang CY; Jing S; Chen GH; Zhang JZ; Xu L; Feng WY; Zhao LB; Fang Y
Int J Clin Pharmacol Ther; 2016 Feb; 54(2):87-95. PubMed ID: 26709597
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for benvitimod quantification in human plasma.
Zhao L; Zhu B; Chen X; Chen G; Chen H; Li Y; Jing S; Fang Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Feb; 885-886():160-5. PubMed ID: 22281235
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis.
Cai L; Chen GH; Lu QJ; Zheng M; Li YZ; Chen J; Zheng J; Zhang FR; Yu JB; Yang S; Li FQ; Xiao SX; Sun QN; Xu JH; Gao XH; Fang H; Gao TW; Hao F; Liu QZ; Tu YT; Li RY; Wang BX; Deng DQ; Zheng QS; Liu HX; Zhang JZ
Chin Med J (Engl); 2020 Nov; 133(24):2905-2909. PubMed ID: 33177393
[TBL] [Abstract][Full Text] [Related]
5. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
Lebwohl MG; Stein Gold L; Strober B; Papp KA; Armstrong AW; Bagel J; Kircik L; Ehst B; Hong HC; Soung J; Fromowitz J; Guenthner S; Piscitelli SC; Rubenstein DS; Brown PM; Tallman AM; Bissonnette R
N Engl J Med; 2021 Dec; 385(24):2219-2229. PubMed ID: 34879448
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial.
Bissonnette R; Poulin Y; Zhou Y; Tan J; Hong HC; Webster J; Ip W; Tang L; Lyle M
Br J Dermatol; 2012 Apr; 166(4):853-60. PubMed ID: 22182053
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial.
Bissonnette R; Bolduc C; Maari C; Nigen S; Webster JM; Tang L; Lyle M
J Eur Acad Dermatol Venereol; 2012 Dec; 26(12):1516-21. PubMed ID: 22077962
[TBL] [Abstract][Full Text] [Related]
8. A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes.
Stein Gold L; Bhatia N; Tallman AM; Rubenstein DS
J Am Acad Dermatol; 2021 Mar; 84(3):624-631. PubMed ID: 32446832
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis.
Paller AS; Stein Gold L; Soung J; Tallman AM; Rubenstein DS; Gooderham M
J Am Acad Dermatol; 2021 Mar; 84(3):632-638. PubMed ID: 32502588
[TBL] [Abstract][Full Text] [Related]
10. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple oral administration.
Scott G; Osborne SA; Greig G; Hartmann S; Ebelin ME; Burtin P; Rappersberger K; Komar M; Wolff K
Clin Pharmacokinet; 2003; 42(14):1305-14. PubMed ID: 14606933
[TBL] [Abstract][Full Text] [Related]
12. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis.
Robbins K; Bissonnette R; Maeda-Chubachi T; Ye L; Peppers J; Gallagher K; Kraus JE
J Am Acad Dermatol; 2019 Mar; 80(3):714-721. PubMed ID: 30612986
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals.
Steudel W; Dingmann C; Zhang YL; Bendrick-Peart J; Clavijo C; Shulze J; Betts R; Christians U
J Clin Pharmacol; 2011 Jan; 51(1):29-39. PubMed ID: 20305057
[TBL] [Abstract][Full Text] [Related]
14. An overview of benvitimod for the treatment of psoriasis: a narrative review.
Lu ST; Kelly KA; Feldman SR
Expert Opin Pharmacother; 2022 Feb; 23(3):327-333. PubMed ID: 34937468
[TBL] [Abstract][Full Text] [Related]
15. Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study.
Bissonnette R; Vasist LS; Bullman JN; Collingwood T; Chen G; Maeda-Chubachi T
Clin Pharmacol Drug Dev; 2018 Jun; 7(5):524-531. PubMed ID: 29389078
[TBL] [Abstract][Full Text] [Related]
16. Application of benvitimod on psoriasis: A systematic review and meta-analysis of randomized controlled trials. A systematic review of benvitimod on psoriasis.
Chen L; Wu Y; Xiao B; Gao X; Sun Y
Therapie; 2022; 77(3):339-347. PubMed ID: 34689959
[TBL] [Abstract][Full Text] [Related]
17. In situ biodistribution and residency of a topical anti-inflammatory using fluorescence lifetime imaging microscopy.
Alex A; Frey S; Angelene H; Neitzel CD; Li J; Bower AJ; Spillman DR; Marjanovic M; Chaney EJ; Medler JL; Lee W; Vasist Johnson LS; Boppart SA; Arp Z
Br J Dermatol; 2018 Dec; 179(6):1342-1350. PubMed ID: 29989149
[TBL] [Abstract][Full Text] [Related]
18. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers.
Paquette JM; Rufiange M; Iovu Niculita M; Massicotte J; Lefebvre M; Colin P; Telmat A; Ranger M
Clin Ther; 2014 Nov; 36(11):1650-64. PubMed ID: 25224876
[TBL] [Abstract][Full Text] [Related]
20. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
